Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease-Reference-Cited by-同舟云学术

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Author:

Yale J.‐F.¹,Bakris G.²,Cariou B.³,Yue D.⁴,David‐Neto E.⁵,Xi L.⁶,Figueroa K.⁷,Wajs E.⁸,Usiskin K.⁷,Meininger G.⁷

Affiliation:

1. Department of Medicine, Royal Victoria Hospital and McGill University Montreal Canada

2. Department of Medicine, The University of Chicago Medicine Chicago IL USA

3. Department of Endocrinology & Center of Clinical Investigation Nantes University Hospital Nantes France

4. Diabetes Centre, Royal Prince Alfred Hospital,University of Sydney Camperdown Australia

5. Núcleo Avançado de Netrologia, Hospital Sírio‐Libanês São Paulo Brazil

6. Janssen Biotech, Inc Spring House PA USA

7. Janssen Research & Development LLC Raritan NJ USA

8. Janssen Research & Development Beerse Belgium

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

Reference26 articles.

Cited by 425 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献